Keywords: hafslund, nycomed, lornoxicam, gains, swiss, approval, inflammatory

Hafslund Nycomed's lornoxicam gains Swiss approval

Article | 22 May 1995

Print This

- Hafslund Nycomed's lornoxicam, for inflammatory degenerative rheumatic diseases, has been approved by the Swiss health authorities.

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in